ECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, Viale Porta Adige 45, I-45100 Rovigo, Italy.
ECSIN-European Center for the Sustainable Impact of Nanotechnology, ECAMRICERT SRL, Viale Porta Adige 45, I-45100 Rovigo, Italy.
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):381-401. doi: 10.1016/j.addr.2016.08.007. Epub 2016 Aug 17.
The fascinating properties of nanomaterials opened new frontiers in medicine. Nanocarriers are useful systems in transporting drugs to site-specific targets. The unique physico-chemical characteristics making nanocarriers promising devices to treat diseases may also be responsible for potential adverse effects. In order to develop functional nano-based drug delivery systems, efficacy and safety should be carefully evaluated. To date, no common testing strategy to address nanomaterial toxicological challenges has been generated. Different cell culture models are currently used to evaluate nanocarrier safety using conventional in vitro assays, but overall they have generated a huge amount of conflicting data. In this review we describe state-of-the-art approaches for in vitro testing of orally administered nanocarriers, highlighting the importance of developing harmonized and validated standard operating procedures. These procedures should be applied in a safe-by-design context with the aim to reduce and/or eliminate the uncertainties and risks associated with nanomedicine development.
纳米材料的迷人特性为医学开辟了新的前沿。纳米载体是将药物输送到特定部位的有用系统。纳米载体具有独特的物理化学特性,有望成为治疗疾病的潜在设备,但也可能导致潜在的不良反应。为了开发功能性基于纳米的药物传递系统,需要仔细评估疗效和安全性。迄今为止,尚未提出针对纳米材料毒理学挑战的通用测试策略。目前,不同的细胞培养模型被用于使用常规的体外测定法来评估纳米载体的安全性,但总体而言,它们产生了大量相互矛盾的数据。在这篇综述中,我们描述了口服纳米载体的体外测试的最新方法,强调了开发协调和验证的标准操作程序的重要性。这些程序应在安全设计的背景下应用,旨在减少和/或消除与纳米医学开发相关的不确定性和风险。